Corina Dutcus, SVP, oncology global clinical development lead, Eisai, highlights how long-term LEAP-002 data provides critical reassurance around Lenvima’s durability and safety in treating ...

The drug discovery research for lecanemab awarded the 9th Bioindustry Award by the Japan Bioindustry Association ...

Corina Dutcus, SVP, oncology global clinical development lead, Eisai, highlights how consistent survival data from the LEAP-002 study reaffirms lenvatinib’s value in first-line treatment of ...

Endometrial Cancer is a type of cancer that begins in the lining of the uterus, most commonly affecting postmenopausal women. Rising prevalence due to increasing obesity rates and aging population, ...

Japanese drugmaker Eisai today revealed that it has launched its Urece (dotinurad) in China as a treatment for gout. Urece ...

Eisai Pharma is set to establish a new Global Capability Center (GCC) in Visakhapatnam, aiming to boost its digital ...

NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value for money”.

Eisai Pharma, a noted human health care pharmaceutical company with a global presence, announced its plans to establish a new ...

The FDA will allow a new dosing schedule for Eli Lilly’s Alzheimer’s drug Kisunla that could lessen a known side effect of ...

The Bioindustry Award, now marking its 9th year, recognizes achievements that have significantly contributed to the development of the bioindustry or are expected to contribute to its future growth.

Visakhapatnam: Eisai Pharma, a noted human health care pharmaceutical company, announced its plans to establish a new global ...

Eisai Pharma to establish Global Capability Center in Visakhapatnam, expanding digital innovation presence in India.